Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05883449 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
A Phase 2 study, sponsored by Affimed.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05883449 is a Phase 2 study that was terminated before completion, run by Affimed. The registered enrollment target is 25 participants.
The verdict
NCT05883449, a Phase 2 study, was terminated before completion, sponsored by Affimed.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Interleukin-2
- DRUG AB-101
- DRUG AFM13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-10-10 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05883449
The ClinicalTrials.gov registry entry for NCT05883449 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Affimed, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05883449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05883449 about?
NCT05883449 is a clinical study titled "Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL". AFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
What is the current status of trial NCT05883449?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2023-10-10. Estimated completion is 2025-06-13.
What interventions are being tested in trial NCT05883449?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Interleukin-2 (DRUG), AB-101 (DRUG), AFM13 (DRUG).
Who is sponsoring clinical trial NCT05883449?
This trial is sponsored by Affimed, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.